if the drug doesn’t reach the target from peripheral vein perhaps we can use central line and get it closer to the heart @johndprent
@Davisite assuming that analogue is correct how could one account for the lack of cardiotoxicity in historical trials. Obviously the cardio protection MOA is working on the heart.
If Bisantrene doesn’t prevent ROS induced cardiotoxicity it must be protecting the heart, by mitigating cardiac fibrosis.
RAC - Charts & Price Action, page-18902
-
- There are more pages in this discussion • 2,973 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |